参芪扶正注射液联合TC方案治疗晚期卵巢上皮癌的临床研究  

Clinical study of Shenqi Fuzheng injection combined with TC regimen in the treatment ofadvanced epithelial ovarian cancer

作　　者：赵文 

机构地区：[1]山东省广饶县人民医院妇科,257300

出　　处：《中国医师进修杂志》2012年第27期22-25,共4页Chinese Journal of Postgraduates of Medicine

摘　　要：目的观察参芪扶正注射液联合TC方案治疗晚期卵巢上皮癌的临床疗效。方法56例晚期卵巢上皮癌患者采用随机数字表法分为治疗组和对照组，每组28例；治疗组给予TC方案化疗，化疗过程中同时给予参芪扶正注射液治疗；对照组仅给予TC方案化疗。观察两组患者T细胞亚群和NK细胞变化情况、生活质量改变、近期疗效及不良反应。结果治疗组治疗后CD3＋、CD4＋、CD4＋/cD8＋及NK细胞水平分别为0．6924±0．0114、0．3738±0．0234、1．48±2．09、0．1849±0．0210，较治疗前的0．6415±0．0422、0．3254±0．0312、1．02±1．18、0．1378±0．0126显著上升，差异有统计学意义（P〈0．05）；治疗后CD8＋水平为0．2528±0．0112，较治疗前的0．3197±O．0265下降，差异有统计学意义（P〈0．05）。与对照组治疗后cD3＋、CD4＋、CD4＋／CD8＋及NK细胞水平（0．6167±0．0347、0．3125±0．0334、1．01±3．31、0．1241．4-0．0324）比较，治疗组治疗后显著上升，差异有统计学意义（尸〈0．05）；对照组治疗后CD8＋水平为0．3101±0．0101，高于治疗组治疗后，差异有统计学意义（P〈0．05）。治疗组有60．7％（17／28）的患者生活质量改善，明显高于对照组的32．1％（9／28），差异有统计学意义（P〈0．05）。治疗组客观有效率为89．3％（25／28），对照组为82．1％（23／28），两组比较差异无统计学意义（P〉0．05）。治疗组的Ⅱ度及以上骨髓抑制（白细胞下降、贫血、血小板下降）发生率明显低于对照组[32．1％（9／28）比71．4％（20／28）、25．0％（7／28）比42．9％（12／28）、17．9％（5／28）比35．7％（10／28）]，差异有统计学意义（P〈0．05）。结论参芪扶正注射液联合TC方案治疗晚期卵巢上皮癌安全、有效，在提高机体免疫力、改善生活质量、保护骨髓功能方面具有重要作用。Objective To observe the clinical efficacy of Shenqi Fuzheng injection combined with TC regimen in the treatment of advanced epithelial ovarian cancer. Methods A total of 56 patients with advanced epithelial ovarian cancer were divided into treatment group and control group by random digits table method with 28 cases each. In treatment group, the patients received TC regimen （paclitaxel plus carboplatin） chemotherapy, while giving patients Shenqi Fuzheng injection in the process of chemotherapy. In control group, the patients only received TC regimen chemotherapy. Tcell subsets and NK cell changes, changes in the quality of life,the recent efficacy and toxicity were observed in two groups. Results CD3＋ CD4＋ CDd/CD8± and NK cell levels after treatment（0.6924 ± 0.0114,0.3738 ± 0.0234,1.48 ± 2.09,0.1849 ± 0.0210） were higher and CD8± level （0.2528 ± 0.0112） was lower than those before treatment （0.6415 ± 0.0422,0.3254 ± 0.0312,1.02 ± 1.18,0.1378 ± 0.0126, 0.3197 ± 0.0265 ） in treatment group （P 〈 0.05 ）. Compared with control group （0.6167 ± 0.0347,0.3125 ± 0.0334,1.01 ± 3.31,0.1241 ± 0.0324,0.3101 ± 0.0101 ）, CD3＋ CD4＋CD4＋CD8＋NK cell levels were increased and CD8＋ was decreased in treatment group （P 〈 0.05 ）. The quality of life improvement in treatment group [60.7% （17/28）] was higher than that in control group [ 32.1% （9/28） ] （P 〈 0.05 ）. There was no significant difference in the objective effective power between two groups [89.3%（25/28） vs. 82.1%（23/28）]（P〉 0.05）. The incidence of more than degree II marrow depression （leucocyte decreasing, anemia, platelet decreasing） in treatment group was lower than that in control group [32.1%（9/28） vs. 71.4%（20/28）,25.0%（7/28） vs. 42.9%（12/28）, 17.9%（5/28） vs. 35.7% （10/28）] （P 〈 0.05）. Conclusion Shenqi Fuzheng injection combined with TC regimen in the treatment of advanced epithelial ovarian cancer is safe and effective, it plays an important role

关 键 词：卵巢肿瘤 药物疗法 参芪扶正注射液 

分 类 号：R737.31[医药卫生—肿瘤]